In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant

Simon D. Van Haren ^{a,b,c}, Lakshmi Ganapathi ^{a,c}, Ilana Bergelson ^a, David J. Dowling ^{a,c}, Michaela Banks ^d, Ronald C. Samuels ^d, Steven G. Reed ^e, Jason D. Marshall ^f, and Ofer Levy ^{a,b,c}.

^aDivision of Infectious Diseases and, ^b*Precision Vaccines Program*, Boston Children's Hospital, 300 Longwood avenue, Boston MA 02115, USA.

^cHarvard Medical School, 25 Shattuck Street, Boston MA 02115, USA.

^dChildren's Hospital Primary Care Center, Boston Children's Hospital, 300 Longwood avenue, Boston MA 02115, USA.

^eInfectious Disease Research Institute, 1616 Eastlake Avenue, Suite 400, Seattle, WA 98102, USA.

^fVaccine Platform Group, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.

Corresponding Author:

Ofer Levy MD, PhD

Division of Infectious Diseases, Boston Children's Hospital.

300 Longwood Avenue, Boston, MA 02115, USA. Phone: + 1 617-919-2904. Fax: + 1 617-730-0255.

e-mail: ofer.levy@childrens.harvard.edu

Abstract

Most infections occur in early life, prompting development of novel adjuvanted vaccines to protect newborns and infants. Several *Toll*-like receptor (TLR) agonists (TLRAs) are components of licensed vaccine formulations or are in development as candidate adjuvants. However, the type and magnitude of immune responses to TLRAs may vary with the TLR activated as well as age and geographic location. Most notably, in newborns, as compared to adults, the immune response to TLRAs is polarized with lower Th1 cytokine production and robust Th2 and anti-inflammatory cytokine production. The ontogeny of TLR-mediated cytokine responses in international cohorts has been reported, but no study has compared cytokine responses to TLRAs between U.S. neonates and infants at the age of 6 months. Both are critical age groups for the currently pediatric vaccine schedule. In this study, we report quantitative differences in the production of a panel of 14 cytokines and chemokines after *in vitro* stimulation of newborn cord blood and infant and adult peripheral blood with agonists of TLR4, including monophosphoryl lipid A (MPLA) and glucopyranosyl lipid Adjuvant aqueous formulation (GLA-AF), as well as agonists of TLR7/8 (R848) and TLR9 (CpG). Both TLR4 agonists, MPLA and GLA-AF, induced greater concentrations of Th1 cytokines CXCL10, TNF and Interleukin (IL)-12p70 in infant and adult blood compared to newborn blood. All the tested TLRAs induced greater infant IFN- α 2 production compared to newborn and adult blood. In contrast, CpG induced greater IFN- γ , IL-1 β , IL-4, IL-12p40, IL-10 and CXCL8 in newborn than infant and adult blood. Overall, to the extent that these *in vitro* studies mirror responses *in vivo*, our study demonstrates distinct age-specific effects of TLRAs that may inform their development as candidate adjuvants for early life vaccines.

Keywords: Neonate, newborn, infant, immune ontogeny, adjuvant, toll-like receptor (TLR).

Introduction

As a key feature of its host defense function, the human immune system recognizes a large variety of microbial products. A variety of hematopoietic cells express Toll-like Receptors (TLRs), a family of pattern-recognition receptors (PRRs) that recognize microbial products, to direct them to exert the appropriate effector function. Dendritic cells (DCs), key antigen-presenting cells at the interface of innate and adaptive immunity, employ PRRs to interpret their surroundings and instruct the adaptive immune system to generate a humoral or cellular immune response. Adjuvanted vaccines leverage the ability of APCs to recognize microbial products and subsequently generate an immune response [1]. Many vaccines contain intrinsic components that engage one or more PRRs, such as Bacille Calmette Guérin (BCG; TLR2 and TLR4) [2, 3], oral polio vaccine (OPV; TLR3) [4, 5] and yellow fever vaccine (YFV; TLRs 7,8, and 9) [6]. Subunit vaccines, made from purified microbial products, may require an adjuvant, to instruct and enhance protective immune responses. Such is the case, for example, for hepatitis B vaccine (HBV), human papilloma vaccine (HPV) and pneumococcal conjugate vaccine (PCV) [7, 8]. Vaccine efficacy is most often evaluated by seroconversion, even though appropriate activation of T-helper (Th)1 or Th17 cells and CD8⁺ cytotoxic T cells may be important for protection in some cases, especially against intracellular pathogens [9-13].

A growing literature documents the cellular and molecular mechanisms by which PRR agonists can serve as adjuvants [14-19]. Adjuvants such as alum and MF59 enhance the immune response to vaccinal antigens that can involve both Th1 and Th2 cells, whereas adjuvants that activate TLR3, -4, -7, -8 and -9 induce a more Th1-biased T-cell response [7, 20]. The type and magnitude of an immune response to a vaccine or an adjuvant can be age-specific. For instance, children under 2 years of age fail to mount an adequate response to pneumococcal polysaccharide vaccine (PPV), an alum-adjuvanted subunit vaccine that is effective in adults [21]. Instead, children under the age of 2 years can effectively be given a pneumococcal conjugate vaccine (PCV), which is adjuvanted with Alum and CRM₁₉₇, a tetanus toxoid that

enables CD4⁺ T cells to mediate seroconversion [22]. *In vivo* and *in vitro* studies have also demonstrated that the innate immune response to pure TLR agonists (TLRAs) is age-dependent and functionally distinct in cord blood mononuclear cells, as compared to their adult counterparts [23-26]. Newborn monocytes and monocyte-derived DCs (moDCs) produce less of the Th1-polarizing cytokine TNF, in response to stimulation through TLR2, -3 or -4, than adult cells [27, 28]. In contrast, newborn monocytes and moDCs produce more interleukin (IL)-6 and IL-10, potentially leading to less Th1 induction [23, 27, 29]. Of note, newborn monocytes, as well as DCs do produce adult-like levels of TNF and IL-1 β in response to TLR7/8 agonists, raising interest in these agonists as potential vaccine adjuvants in early life [23, 30-32].

In this study we employed a whole blood assay (WBA) to study the ontogeny of cytokine responses to four TLRAs: monophosphoryl lipid A (MPLA; TLR4), an aqueous formulation the novel glucopyranosyl lipid antigen (GLA-AF; TLR4) [33, 34], resiquimod (R848; TLR7/8) and CpG oligonucleotide ODN 2395 (TLR9). Although both MPLA and GLA are based on the core lipid A of LPS, there are important differences between these two molecules, including that the latter is synthetic [34]. We measured the production of 14 cytokines [35] and potential reactogenicity biomarker prostaglandin E₂ (PGE₂) [36] after stimulation of umbilical cord blood, peripheral blood from 6-month old infants and 18-40-year old adults. We noted that the cytokine response varied by age and TLRA. Cytokine production in response to TLR7/8 agonist R848 was comparable between all age groups tested. While the production of Th1 cytokines by newborn cells was impaired, blood from 6-month old infants produced adult-like levels of Th1 cytokines in response to TLR4 agonists. We also observed that CpG induced robust cytokine induction in newborn blood and GLA-AF demonstrated greater potency and efficacy than MPLA in inducing Th-polarizing cytokine production in infant blood.

Materials and Methods:

Ethics Statement

Non-identifiable cord blood samples were collected with approval from the Ethics Committee of The Beth Israel Deaconess Medical Center, Boston, MA (protocol number 2011P-000118). All experiments were performed in accordance with relevant institutional and national guidelines, regulations, and local Institutional Review Board (IRB) approval. Adult participants provided de-identified blood samples after written informed consent in accordance with a protocol approved by the IRB of Boston Children's Hospital (BCH), Boston, MA (protocol number X07- 05-0223). Infant donors were recruited from the Children's Hospital Primary Care Clinic during routine outpatient visits to receive vaccines as scheduled (diphtheria, tetanus, acellular pertussis (DTaP; 7 of 8 infants), hepatitis B vaccine (HBV; 1 of 8), rotavirus (RV; 7 of 8), [haemophilus B conjugate vaccine \(PRP-T\)](#), pneumococcal conjugate vaccine (PCV13; 7 of 8), inactivated poliovirus (IPV; 3 of 8)). In order to reduce the burden on enrolled infants, and to reduce drop-outs from scheduled immunization, blood draws in this age group occurred immediately after routine 6-month immunizations.. Informed consent was provided by parents for collection of de-identified infant blood samples in accordance with the BCH IRB (protocol number P00010750). Blood was drawn into a syringe with no additives, and then immediately added to 5 ml pyrogen-free polypropylene tubes (Sigma-Aldrich Co. LLC. St Louis, MO, USA) containing pyrogen-free heparin (American Pharmaceutical Partners, Inc.; Schaumburg, IL, USA) in a 1:50 ratio to blood. Blood and heparin were mixed by inversion.

TLR Agonists and Assay Reagents

The following TLRAs were used at the concentrations noted in the figure legends: MPLA (TLR4), R848 (TLR7/8), and ODN 2395 (TLR9) all from from InVivogen (San Diego, CA). GLA-AF (TLR4) was from the Infectious Diseases Research Institute (IDRI; Seattle, WA).

124

125 **Blood Sample Processing and *in vitro* Stimulation**

126 For assessment of TLRA activity in whole blood, we used an adaptation of the method of
127 Kollmann et al [37]. Neonatal cord blood, infant peripheral blood, or adult peripheral blood was
128 diluted 5x with sterile pre-warmed (37°C) RPMI 1640 medium (Invitrogen, Carlsbad, CA) and
129 135 µL of the suspension was added to each well of a 96 well round-bottom plate (Becton
130 Dickinson, Franklin Lakes, NJ, USA) containing 15 µl freshly prepared specific TLRAs at 10x the
131 final concentration. Suspensions containing 150 µl/well were gently mixed by pipetting and
132 incubated for 18 h at 37°C in a humidified incubator at 5% CO₂. After culture, plates were
133 centrifuged at 500 x g and 3 aliquots of 35 µl of supernatant were carefully removed by pipetting
134 without disturbing the cell pellet. Supernatants derived from human leukocyte stimulations were
135 assayed by ELISA for TNF (BD Biosciences, San Jose, CA, USA) and PGE₂ (Cayman
136 Chemicals; Ann Arbor, MI) and by multiplexing bead array (Millipore).

137

138 **Cytokine measurement by multi-analyte fluorescent bead-based array**

139 Cytokine concentrations in supernatants derived from whole blood assays was measured by
140 multi-analyte bead array (Milliplex) using a custom-designed Cytokine Human Magnetic Panel
141 from Invitrogen – Life Technologies (Carlsbad, CA, USA), including IFN-α2, IFN-γ, IL-10, IL-
142 12p40, IL-12p70, IL-1β, IL-6, and TNF. Results were obtained with a MAGPIX system with
143 Luminex xPONENT software (both from Luminex Corp., Austin, TX, USA). Cytokine
144 concentrations were determined using Milliplex Analyst (version 3.5.5.0, Millipore) software.

145

146 **Statistical Analyses and Graphics**

147 Data were analyzed using Prism for MacIntosh v. 5.0b (GraphPad Software Inc., San Diego,
148 CA). Data in figures represent means ± SEM. Differences between conditions at a single
149 concentration were evaluated using a Student's t-test, and differences across a range of

150 different concentrations were evaluated via repeated measured analysis of variance (RM-
151 ANOVA), and p values <0.05 were considered significant.

Results

The age specific effects of four different TLRAs were evaluated *in vitro* using whole blood from three cohorts: (a) cord blood from full term newborns (mean gestational age of 39 weeks), (b) infant peripheral blood donors (mean age of 6 months) and (c) adult peripheral blood donors (mean age of 35 years; n = 8 per cohort). Concentration-dependent cytokine production in response to MPLA, GLA-AF, R848 and CpG was quantified after stimulation of RPMI-diluted blood. The reduced ability of newborn blood to produce Th1 cytokines in response to many TLRAs is well described [24, 29, 37]. To investigate the production of 14 cytokines and PGE₂, we tested 12-point concentration-response curves for each of these analytes to determine the maximal response to TLRAs by each age group and for each analyte. These maximal responses were evaluated for statistically significant differences between age groups in Fig. 1 (for a complete overview of dose-response curves, see also Supplementary Fig. 1 and Table 1). Consistent with prior reports [23, 24, 29, 38, 39], the production of IL-10, IL-6 and CXCL8 was higher in newborn whole blood than in adult whole blood after stimulation with TLR4 or TLR7/8 agonists. Newborn blood produced greater concentrations of these cytokines than infant blood, and were highest in newborns after stimulation with CpG (Fig. 1). However, differences in maximal response between all age groups in CpG-stimulated blood as well as between newborns and adults in GLA- or R848-stimulated blood were not statistically significant. The differences between the 12-point dose-response curves under all these conditions were statistically significant when measured by RM-ANOVA (Supplementary Fig. 1, see also Fig. 4). As previously reported for moDCs [32], a higher production of IL-1 β by newborns after stimulation with R848 was also observed. Panels E-F indicate that the production of chemokines CCL2, CCL3 and CCL5 in response to TLRAs is more distinct in newborns as well. Of note, TLR4-mediated production of the pro-inflammatory cytokines IFN- α , GM-CSF and TNF in response to MPLA and GLA-AF was highest in the infant age group. Although the higher

production of IFN- α in infants after stimulation with MPLA, GLA-AF or CpG was not statistically significant from that of other age groups, these TLRAs were more potent in infant than in newborn or adult blood (MPLA infant 62.5 ng/ml vs newborn 1000 ng/ml, adult 500 ng/ml; GLA infant 250 ng/ml vs. newborn 1000 ng/ml, adult 500 ng/ml; CpG infant 6.25 μ g/ml vs. newborn and adult 12.5 μ g/ml; see also Supplementary Figure 1). TLR4 and TLR7/8-mediated production of the Th1 cytokines CXCL10, IL12 and IFN- γ demonstrated age-dependency, from least production in newborns, intermediate in infants to most in adults. In contrast, newborn whole blood demonstrated adult-level CpG-induced Th1 cytokine production. CpG results, as well as CXCL10 production in response to GLA were statistically significant when comparing the dose-response curves using RM-ANOVA.

A direct comparison of the cytokine profiles induced by the TLR4 agonists, MPLA and GLA-AF, (Fig. 2) shows that both GLA-AF and MPLA induce a similar cytokine profile that changes per age group (Fig. 2A, E, I), with a number of exceptions, which are highlighted in the sub-panels. For the radar graphs a fixed concentration of TLR4 agonist is displayed (62.5 ng/ml). At this concentration near-maximal responses were consistently observed in both GLA- and MPLA-stimulated samples for most cytokines. In general, GLA-AF was significantly more potent and more effective than MPLA at inducing Th-polarizing cytokine production *in vitro*, including (a) greater neonatal IL-1 β , IL-6 and CCL4 production (Fig. 2B-D), (b) greater CXCL10 production in both infants and in adults (Fig. 2F,J), greater TNF and IL-10 in infants (G-H), and greater IFN- γ and IL12p70 in adults (K-L).

In response to the TLR4 agonist GLA-AF, newborns demonstrated impaired production of Th1-associated cytokines typical of their responses to other TLRAs [27, 29, 37, 40, 41] (Fig. 3). Age-dependent differences were noted in the production of all cytokines measured at a fixed concentration (62.5 ng/ml; Fig. 3A). While the production of Th1 cytokines CXCL10, IFN- γ , and IL12p70 was approximately one log lower in newborns as compared to adults as well as infants

(Fig. 3 B-D), the production of Th2 cytokine IL-6 and chemokines CCL2 and CXCL8 (formerly IL-8) and the anti-inflammatory cytokine IL-10 were similar to or greater than adult levels in newborns as well as infants (F-I). Of note, GLA-induced production of IFN- α was greater in infants as compared to newborns and adults (E). Indeed, newborns and adults were significantly different at multiple agonist concentrations (Student's t-test), and across the entire concentration spectrum (repeated-measures ANOVA; Fig. 3B-I).

In contrast to the pattern with other TLRAs, CpG induced the greatest cytokine response in newborns as compared to infants or adults (Fig. 4A). Neonatal CpG-induced production of IFN- γ , IL-1 β , IL-6, IL-12p40, IL-10, CCL2 and CXCL8 was greater than that of infants and adults. As has been noted in other cohorts [31, 32, 40], R848 induced the most robust cytokine production of all TLRAs tested in all three age groups- i.e., newborns, infants and adults (Fig. 4B; Supplementary Fig. 1). Prostaglandin E₂ (PGE₂) exerts multiple effects on the immune system [42, 43], and has been suggested based on studies of monoMac cells as a potential *in vitro* biomarker for adjuvant reactogenicity [36]. Interestingly, newborn blood demonstrated the greatest basal and TLRA-induced levels of PGE₂ (Fig. 5). PGE₂ secretion in response to TLRAs was most pronounced in response to R848 (Fig. 5B-D).

Discussion

In vitro experiments using whole blood from healthy donors is a practical approach to assess the immunological activity of pathogens or (potential) vaccine adjuvants [40, 44-47], and has revealed age-specific differences in the immune response to TLRAs [27, 31, 37, 48-51]. Of all three age groups compared in the present study, the infant age group (age 2-6 months) receives the most vaccines within the vaccination schedules of most industrialized/wealthy countries, including in the U.S. and E. U. [52]. Paradoxically, this is also the age group in which the immune response is the least studied *in vitro*, likely due to limitations in accessibility and restrictions in blood volume. In a prior study, the production of 9 cytokines was measured in a whole blood assay with newborns, adults and infants of age 3, 6, 9 and 12 months [39] after stimulation with LPS or CpG. Both agonists were used at a single concentration only. In this study, newborn, infant and adult peripheral blood was used to investigate the innate immune response to candidate vaccine adjuvants MPLA, GLA-AF, R848 and CpG. We used these agonists at a range of 12 different concentrations, allowing not only for comparison of maximal cytokine responses, but also for comparison of potency of these adjuvants between the age groups. The most commonly measured cytokines in a whole-blood assay are TNF and IL-6. In this study we characterized production of 14 cytokines representing different immune functions, such as innate immune cell activation, T-cell polarization and chemoattraction.

As compared to adults, the immune system of newborns is characterized by skewed TLR-mediated cytokine production, with impaired production of Th1-polarizing cytokines such as TNF and IL-12p70, but robust production of Th2/Th17-polarizing IL-6. [23, 37]. Newborn lymphocytes include predominantly immature B cells [53], and naïve CD4⁺ T lymphocytes are skewed to develop into T-helper 2 cells [26]. Limited information is available about the extent to which some of the unique features of the newborn immune system extend into early childhood [39, 40]. Studying the innate immune system of 2-6 month old infants in response to vaccine

adjuvants is relevant, as this is the age group that receives the most vaccines in developed countries.

The functionally distinct impairment in secretion of Th1 cytokines in response to TLRAs in newborns is not observed in infants, which may explain why many vaccines are effective in infants but not in newborns (Figure 1). Interestingly, infants (mean age 6 months) were the only age group that produces significant amounts of IFN- α and TNF in response to TLR4 stimulation (Fig. 1 H-J). In order to reduce the burden on enrolled infants, and to reduce drop-outs from scheduled immunization, blood draws in this age group occurred immediately after routine 2-month immunizations, which may have modulated the cytokine response in the whole-blood assay. This is unlikely, however, as peripheral blood collection took place within an hour of immunization and baseline levels of any cytokine were not significantly different in any age group as compared to the other age groups. In addition, a peak IFN- α response at 6 months has been previously described [49].

To our knowledge, ours is the first study characterizing the activity of GLA-AF across three age groups, including newborns and infants. Prior to our current study all published (Pubmed as of March 29, 2016) studies reporting cytokine production of newborn cells in response to TLR4 stimulation employed LPS or MPLA. Although structurally similar to MPLA, GLA is a synthetic product with molecular and immunological properties that are distinct from MPLA [34, 54]. GLA-AF was more potent and effective than MPLA in inducing multiple cytokines (Figure 2). In newborns, the production of CCL4, IL-1 β and IL-6 is ~10-fold more after stimulation with GLA-AF than MPLA. Impairment in Th1 cytokine production was much less profound in infants (Figures 2 and 3). Specific differences between the TLR4 agonists in infants include greater production of TNF, IL-10 and CXCL10 after stimulation with GLA-AF than MPLA. Most strikingly, GLA-AF induced a significant increase in Th1-polarizing cytokines including IFN- γ , IL-12p70 and CXCL10.

Compared to adults, newborns produced less TNF and more IL-6 in response to a TLR4 agonist (Fig. 2-4), as has been noted previously [23, 27]. We also noted impaired TLR4-mediated production of additional Th1-cytokines, including CXCL10, IFN- γ and IL-12p70. In contrast, neonatal production of non-Th1 cytokines, such as IL-6, IL-10 and CXCL8, was equal or greater than in adults. In contrast to the pattern with other TLRAs, CpG, a TLR9 agonist, induced the greatest cytokine response in newborns as compared to infants or adults (Figure 4), with the exception of CXCL10, TNF, IL-12p40 and IFN- α . Prior studies have reported impaired responses of human newborn plasmacytoid DCs to CpG, but robust IFN- α production by neonatal plasmacytoid DCs (pDCs) in response to viruses that engage TLR7 and TLR9 [55-57]. The discrepancy between our results demonstrating robust CpG-induced cytokines in newborns and cited literature is currently unclear though we note our study employed 5x diluted blood instead of whole blood or purified pDCs. Neonatal plasma is rich in immunomodulatory molecules and dilution may account for modulation of cytokine responses to TLRAs. Of note, it is uncertain what the relevant concentration (e.g., volume/volume) of plasma components may be at local tissues or sites of immunization, though it is unlikely to be 100%.

Moreover, the absolute number of pDCs per volume of blood is highest at birth, and declines with age [58, 59], providing an alternative explanation for the observed robust response to CpG in newborn blood, despite the above-mentioned functional impairment of these cells. Speculation as to the contribution of cell type composition to the observed cytokine responses in each age group is complicated by the fact that absolute quantity of several myeloid and lymphoid subsets is higher early in life, but the function and phenotype of these cells is more immature in nature [53, 60].

Of all the adjuvant TLRAs evaluated in our study, the TLR7/8 agonist R848 induced the most robust cytokine production at all age groups- newborns, infants and adults (Figure 4B).

In addition to cytokine production, we also measured production of PGE₂, an immunologically active mediator that modulates immunity [43, 61]. PGE₂ plays a key role in the modulation of innate [29, 43, 61] as well as adaptive immune responses [62-64] and provides additional characterization of age- and adjuvant-specific differences in leukocyte activation. Of note, adjuvant-induced PGE₂ induction by the monomac6 monocytic cell-line tested *in vitro* has been linked to reactogenicity *in vivo* [36], though it has yet to be established that PGE₂ serves as a reactogenicity biomarker in other *in vitro* model systems, such as whole blood [65]. We noted that basal levels of PGE₂ were elevated in newborns and TLRAs induced robust neonatal PGE₂ induction (Fig. 5). This age-specific effect was apparently diminished by 6 months of age, as infant plasma PGE₂ levels were comparable to those of adults.

Our study features a number of important strengths. To our knowledge, ours is the first study that: evaluated the ability of TLR-activating adjuvants to induce cytokine and chemokine production in U.S.-based infants, compared commonly used TLRAs to MPLA and to GLA-AF, a novel and promising adjuvant currently being evaluated in human clinical trials [33, 66], and that included measurement of PGE₂, a potential biomarker of reactogenicity [36]. Our study also has some limitations. It was an *in vitro* study, and although recent studies suggest that TLRAs active *in vitro* are also active in humans *in vivo* [31, 32, 67, 68], the extent of correlation with responses *in vivo* remains uncertain. In addition, our study size was limited, and infant blood was drawn after routine immunization, reflecting the well described challenges of enrolling U.S. infant cohorts [69, 70].

Overall, our study reveals significant differences in TLRA-induced cytokine production *in vitro*, varying with both TLRA and age group. To the extent that our *in vitro* data reflect the bioactivity of these TLRAs *in vivo*, our results suggest the importance of accounting for age-and adjuvant-specific responses in informing future pediatric vaccine development. In particular, CpG induced robust production of an array of Th-polarizing cytokines and chemokines in newborn blood and the novel adjuvant GLA-AF was more potent and effective than MPLA in inducing Th polarizing

318 cytokine production in all age groups. Further *in vitro* and *in vivo* studies, including those in
319 appropriate animal models, are needed to assess the potential of CpG, GLA-AF and other
320 TLRAs as candidate pediatric vaccine adjuvants.

Acknowledgements

OL's laboratory is supported by a Boston Children's Hospital Department of Medicine award to the *Precision Vaccines Program* as well as Global Health (OPPGH5284) and Grand Challenges Explorations (OPP1035192) awards from the Bill & Melinda Gates Foundation and by NIH grants 1R01AI100135-01 and 3R01AI067353-05S1 and National Institute of Allergy & Infectious Diseases Adjuvant Discovery Program, Contract No. HHSN272201400052C. SvH was supported by an Early Career Award from the Thrasher Research Fund. We thank the Labor and Delivery staff at The Brigham & Women's Hospital, Boston, MA and Beth Israel Deaconess Medical Center Boston, MA for their kind assistance with sample acquisition.

Figure legends

Fig. 1. Age-dependent TLR agonist-induced cytokine production in whole blood.

Newborn, infant or adult peripheral blood was diluted 5x and stimulated with MPLA (TLR4; 0.98-1000 ng/ml), GLA-AF (TLR4; 0.98-1000 ng/ml), R848 (TLR7/8; 0.098-100 μ M) or CpG (TLR9; 0.049-50 μ g/ml). Maximal response was determined for each age group (N=Newborn, I=Infant and A=Adult). Comparison of TLR-induced cytokine production between newborns, infants and adults is shown. Stars indicate statistical significance between age groups indicated as measured by Student's t-test. (* p <0.05, ** p <0.01, *** p <0.001)

Fig. 2. GLA-AF is more potent and effective than MPLA in inducing cytokines in all age groups.

Newborn, infant or adult blood was diluted 5x and stimulated with MPLA or GLA-AF at concentrations indicated. **A,E,I)** Radar graphs demonstrate the magnitude of production of 14 cytokines at a fixed concentration of GLA-AF and MPLA, both 62.5 ng/ml. **B-L)** Concentration-response graphs compare the production of CCL4 (B), CXCL10 (F,J), IL-1 β (C), TNF (G), IFN- γ (K), IL-6 (D), IL-10 (H) and IL-12p70 (L) between MPLA and GLA-AF at concentrations as indicated. Stars adjacent to a curve indicate statistical significance at that concentration as measured by Student's t-test. Stars above the connector-lines indicate statistical significance between the connected curves, as measured by 2-way ANOVA. (* p <0.05, ** p <0.01, *** p <0.001)

Fig. 3. GLA-AF induces robust Th2 cytokine production in newborns and infants as well as age-dependent maturation Th1 cytokine production.

Newborn, infant or adult blood was diluted 5x and stimulated with GLA-AF at the concentrations indicated. **A)** Radar plot demonstrates the magnitude of production of 14 cytokines at a fixed concentration of GLA-AF, 62.5 ng/ml. **B-I)** Concentration-response graphs compare the production of CXCL10 (B), IFN- γ (C), IL-12p70 (D), IFN- α (E), IL-6 (F), CXCL8 (IL-8) (G), IL-10 (H) and CCL2 (I) between

newborns, infants and adults at concentrations of GLA-AF indicated. Stars adjacent to a curve indicate statistical significance at that concentration as measured by Student's t-test. Stars above the connector-lines indicate statistical significance between the curves connected by the connector-line, as measured by 2-way ANOVA. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$)

Fig. 4. Robust R848- and CpG-induced cytokine production in human newborn cord blood. Newborn, infant or adult blood was diluted 5x and stimulated with **A)** CpG (TLR9 agonist; 6.25 $\mu\text{g/ml}$) or **B)** R848 (TLR7/8 agonist; 12.5 μM). Radar graph compares the magnitude of production of 14 cytokines between newborns, infants and adults as measured by multiplex assay.

Fig. 5. Newborn cord blood demonstrates higher basal and TLR agonist-induced Prostaglandin E₂ concentrations than infant and adult blood. Newborn, infant and adult blood was diluted five-fold with RPMI, then stimulated with buffer control, MPLA (highest concentration 1 $\mu\text{g/ml}$), GLA-AF (highest concentration 1 $\mu\text{g/ml}$), R848 (highest concentration 100 μM) or CpG (highest concentration 50 $\mu\text{g/ml}$) as indicated and ten 2-fold dilutions thereof. **A)** Basal levels of PGE₂ in blood stimulated with vehicle only shows higher levels of basal PGE₂ in newborns. **B-D).** After stimulation with MPLA, GLA-AF, R848 or CpG at concentrations indicated, the production of PGE₂ was greater in newborn blood as compared to infant and adult blood. Stars adjacent to a curve indicate statistical significance at that concentration as measured by Student's t-test. Stars above the connector-lines indicate statistical significance between the curves connected by the connector-line, as measured by 2-way ANOVA. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$)

Table 1. Age-dependent TLRA-induced cytokine production

Averaged baseline (vehicle control condition) and maximal cytokine levels for each study age group and agonist, as well as the agonist concentration (ng/ml for MPLA and GLA; μ M for R848 and μ g/ml for CpG) required for the maximal cytokine response. p-Values of 2-way ANOVA comparing the age groups are indicated. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$)

Supplementary Fig. 1. Age-dependent TLRA-induced cytokine production. Newborn, infant or adult blood was diluted 5x and stimulated with MPLA (0.98-1000 ng/ml), GLA-AF (0.98-1000 ng/ml), R848 (0.098-100 μ M) or CpG (0.049-50 μ g/ml). Stars adjacent to a curve indicate statistical significance at that concentration as measured by Student's t-test. Stars above the connector-lines indicate statistical significance between the curves connected by the connector-line, as measured by 2-way ANOVA. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$)

References

- [1] Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. *Immunol Rev.* 2011;239:178-96.
- [2] Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, et al. TLR2 and TLR4 serve distinct roles in the host immune response against *Mycobacterium bovis* BCG. *J Leukoc Biol.* 2003;74:277-86.
- [3] Yadav M, Schorey JS. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. *Blood.* 2006;108:3168-75.
- [4] Harris KG, Coyne CB. Enter at your own risk: how enteroviruses navigate the dangerous world of pattern recognition receptor signaling. *Cytokine.* 2013;63:230-6.
- [5] Oshiumi H, Okamoto M, Fujii K, Kawanishi T, Matsumoto M, Koike S, et al. The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. *J Immunol.* 2011;187:5320-7.
- [6] Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. *J Exp Med.* 2006;203:413-24.
- [7] Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity.* 2010;33:492-503.
- [8] Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. *Vaccine.* 2012.
- [9] Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. *J Gen Virol.* 2014;95:1043-54.

- [10] Milicic A, Kaur R, Reyes-Sandoval A, Tang CK, Honeycutt J, Perrie Y, et al. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. *PLoS One*. 2012;7:e34255.
- [11] Holt PG. Functionally mature virus-specific CD8(+) T memory cells in congenitally infected newborns: proof of principle for neonatal vaccination? *J Clin Invest*. 2003;111:1645-7.
- [12] Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for *Plasmodium vivax* with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. *Infect Immun*. 2011;79:3492-500.
- [13] Allen AC, Mills KH. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. *Expert Rev Vaccines*. 2014;13:1253-64.
- [14] Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, et al. MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action. *J Immunol*. 2012.
- [15] Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. *Immunol Lett*. 2012.
- [16] Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. *PLoS One*. 2012;7:e51618.
- [17] MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. *Proc Natl Acad Sci U S A*. 2011;108:7914-9.
- [18] Mori A, Oleszycka E, Sharp FA, Coleman M, Ozasa Y, Singh M, et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. *Eur J Immunol*. 2012.

442 [19] Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular
443 signatures of human vaccine adjuvants. *Proc Natl Acad Sci U S A*. 2008;105:10501-6.

444 [20] Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, et al.
445 MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus
446 Germinal Center Responses in Adult and Early Life. *J Immunol*. 2015;194:4836-45.

447 [21] Balmer P, Borrow R, Arkwright PD. The 23-valent pneumococcal polysaccharide vaccine
448 does not provide additional serotype antibody protection in children who have been primed with
449 two doses of heptavalent pneumococcal conjugate vaccine. *Vaccine*. 2007;25:6321-5.

450 [22] Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al. Safety and
451 immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and
452 toddlers. *Pediatr Infect Dis J*. 1999;18:757-63.

453 [23] Angelone DF, Wessels MR, Coughlin M, Suter EE, Valentini P, Kalish LA, et al. Innate
454 immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in
455 vitro and in vivo. *Pediatr Res*. 2006;60:205-9.

456 [24] Levy O. Innate immunity of the human newborn: distinct cytokine responses to LPS and
457 other Toll-like receptor agonists. *J Endotoxin Res*. 2005;11:113-6.

458 [25] Willems F, Vollstedt S, Suter M. Phenotype and function of neonatal DC. *Eur J Immunol*.
459 2009;39:26-35.

460 [26] Zaghoulani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the
461 shortcomings of dendritic cells. *Trends Immunol*. 2009;30:585-91.

462 [27] Levy O, Zarembka KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective
463 impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma
464 reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and
465 imiquimod, but preserves the response to R-848. *J Immunol*. 2004;173:4627-34.

- [28] Lemoine S, Jaron B, Tabka S, Ettreiki C, Deriaud E, Zhivaki D, et al. Dectin-1 activation unlocks IL12A expression and reveals the T1 potency of neonatal dendritic cells. *J Allergy Clin Immunol*. 2015.
- [29] Belderbos ME, Levy O, Stalpers F, Kimpen JL, Meyaard L, Bont L. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. *PLoS One*. 2012;7:e33419.
- [30] Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, et al. The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes. *PLoS One*. 2013;8:e58164.
- [31] Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. *Blood*. 2006;108:1284-90.
- [32] Philbin VJ, Dowling DJ, Gallington LC, Cortes G, Tan Z, Suter EE, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. *J Allergy Clin Immunol*. 2012;130:195-204 e9.
- [33] Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. *PLoS One*. 2014;9:e88979.
- [34] Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. *PLoS One*. 2011;6:e16333.
- [35] Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. *J Allergy Clin Immunol*. 2011;127:701-21 e1-70.
- [36] Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, et al. 159-Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. *Vaccine*. 2012.

492 [37] Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al. Neonatal
493 innate TLR-mediated responses are distinct from those of adults. *J Immunol.* 2009;183:7150-60.

494 [38] Dembinski J, Behrendt D, Reinsberg J, Bartmann P. Endotoxin-stimulated production of IL-
495 6 and IL-8 is increased in short-term cultures of whole blood from healthy term neonates.
496 *Cytokine.* 2002;18:116-9.

497 [39] Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, Van Damme P, et al. Acquisition of
498 adult-like TLR4 and TLR9 responses during the first year of life. *PLoS One.* 2010;5:e10407.

499 [40] Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, et al. Age-dependent
500 maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. *PLoS One.*
501 2011;6:e18185.

502 [41] Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system
503 selectively inhibits TLR-mediated TNF-alpha production in the human newborn. *J Immunol.*
504 2006;177:1956-66.

505 [42] Shimabukuro-Vornhagen A, Liebig TM, Koslowsky T, Theurich S, von Bergwelt-Baildon
506 MS. The ratio between dendritic cells and T cells determines whether prostaglandin E has a
507 stimulatory or inhibitory effect. *Cell Immunol.* 2013;281:62-7.

508 [43] Rodriguez M, Domingo E, Municio C, Alvarez Y, Hugo E, Fernandez N, et al. Polarization of
509 the Innate Immune Response by Prostaglandin E2: a Puzzle of Receptors and Signals. *Mol*
510 *Pharmacol.* 2013.

511 [44] Blankley S, Graham CM, Howes A, Bloom CI, Berry MP, Chaussabel D, et al. Identification
512 of the key differential transcriptional responses of human whole blood following TLR2 or TLR4
513 ligation in-vitro. *PLoS One.* 2014;9:e97702.

514 [45] Coch C, Luck C, Schwickart A, Putschli B, Renn M, Holler T, et al. A Human In Vitro Whole
515 Blood Assay to Predict the Systemic Cytokine Response to Therapeutic Oligonucleotides
516 Including siRNA. *PLoS One.* 2013;8:e71057.

517 [46] Strunk T, Power Coombs MR, Currie AJ, Richmond P, Golenbock DT, Stoler-Barak L, et al.
518 TLR2 mediates recognition of live *Staphylococcus epidermidis* and clearance of bacteremia.
519 PLoS One. 2010;5:e101111.

520 [47] Marchant EA, Kan B, Sharma AA, van Zanten A, Kollmann TR, Brant R, et al. Attenuated
521 innate immune defenses in very premature neonates during the neonatal period. *Pediatr Res*.
522 2015;78:492-7.

523 [48] Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate Immune Function by Toll-like
524 Receptors: Distinct Responses in Newborns and the Elderly. *Immunity*. 2012;37:771-83.

525 [49] Reikie BA, Adams RC, Ruck CE, Ho K, Leligidowicz A, Pillay S, et al. Ontogeny of Toll-Like
526 Receptor Mediated Cytokine Responses of South African Infants throughout the First Year of
527 Life. *PLoS One*. 2012;7:e44763.

528 [50] Shey MS, Nemes E, Whatney W, de Kock M, Africa H, Barnard C, et al. Maturation of
529 innate responses to mycobacteria over the first nine months of life. *J Immunol*. 2014;192:4833-
530 43.

531 [51] Ganapathi L, Van Haren S, Dowling DJ, Bergelson I, Shukla NM, Malladi SS, et al. The
532 Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production
533 by Human Newborn and Adult Leukocytes. *PLoS One*. 2015;10:e0134640.

534 [52] Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines. *Sci Transl Med*.
535 2011;3:90ps27.

536 [53] Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell
537 subpopulations from infancy to adulthood. *Clin Exp Immunol*. 2010;162:271-9.

538 [54] Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, et al. MyD88 and
539 TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist
540 adjuvant. *Eur J Immunol*. 2013;43:2398-408.

541 [55] Zhang X, Lepelley A, Azria E, Lebon P, Roguet G, Schwartz O, et al. Neonatal
542 Plasmacytoid Dendritic Cells (pDCs) Display Subset Variation but Can Elicit Potent Anti-Viral
543 Innate Responses. PLoS One. 2013;8:e52003.

544 [56] Danis B, George TC, Goriely S, Dutta B, Renneson J, Gatto L, et al. Interferon regulatory
545 factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J
546 Immunol. 2008;38:507-17.

547 [57] De Wit D, Orlslagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, et al. Blood
548 plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human
549 newborns. Blood. 2004;103:1030-2.

550 [58] Orsini G, Legitimo A, Failli A, Massei F, Biver P, Consolini R. Enumeration of human
551 peripheral blood dendritic cells throughout the life. Int Immunol. 2012;24:347-56.

552 [59] Heinze A, Elze MC, Kloess S, Ciocarlie O, Konigs C, Betz S, et al. Age-matched dendritic
553 cell subpopulations reference values in childhood. Scand J Immunol. 2013;77:213-20.

554 [60] Peoples JD, Cheung S, Nesin M, Lin H, Tatad AM, Hoang D, et al. Neonatal cord blood
555 subsets and cytokine response to bacterial antigens. Am J Perinatol. 2009;26:647-57.

556 [61] Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21-
557 8.

558 [62] Landi A, Babiuk LA, van Drunen Littel-van den Hurk S. Dendritic cells matured by a
559 prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature
560 and Th1-biased than dendritic cells treated with TNF-alpha or LPS. Immunobiology.
561 2011;216:649-62.

562 [63] Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, Kalinski
563 P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to
564 produce CCL19 and attract naive T cells. Blood. 2010;116:1454-9.

565 [64] Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor
566 for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood*.
567 2002;100:1354-61.

568 [65] Mastelic B, Garcon N, Del Giudice G, Golding H, Gruber M, Neels P, et al. Predictive
569 markers of safety and immunogenicity of adjuvanted vaccines. *Biologicals*. 2013.

570 [66] Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, et al. TLR4 ligand
571 formulation causes distinct effects on antigen-specific cell-mediated and humoral immune
572 responses. *Vaccine*. 2013.

573 [67] Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, et al. HIV Gag protein
574 conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and
575 CD8+ T cell responses in nonhuman primates. *Proc Natl Acad Sci U S A*. 2005;102:15190-4.

576 [68] Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, et al. Toll-like receptor
577 agonists influence the magnitude and quality of memory T cell responses after prime-boost
578 immunization in nonhuman primates. *J Exp Med*. 2006;203:1249-58.

579 [69] Bavdekar SB. Pediatric clinical trials. *Perspect Clin Res*. 2013;4:89-99.

580 [70] McKechnie L, Gill AB. Consent for neonatal research. *Arch Dis Child Fetal Neonatal Ed*.
581 2006;91:F374-6

Table 1

Agonist	Cytokine	Newborn Baseline	Newborn Max resp.	Newborn [Agonist]	Infant Baseline	Infant Max resp.	Infant [Agonist]	Adult Baseline	Adult Max resp.	Adult [Agonist]	RM-ANOVA NB vs IN	RM-ANOVA IN vs AD	RM-ANOVA NB vs AD
MPLA	CXCL10	23.40	94.84	1000.00	30.60	947.78	1000.00	14.39	1900.63	1000.00	*0.0188	0.4403	*0.0152
	CCL4	30.51	5091.51	1000.00	43.43	4767.39	1000.00	83.35	5084.25	1000.00	***0.0006	0.7342	***0.0009
	CCL5	2521.03	4649.00	1000.00	2861.61	4514.48	1000.00	1951.22	2517.60	1000.00	0.1259	***<0.0001	***<0.0001
	IFN- γ	1.83	8.85	125.00	13.93	103.76	3.91	4.73	78.23	1000.00	*0.0130	*0.2260	**0.0019
	TNF	20.44	73.82	1000.00	23.71	225.35	1000.00	40.73	201.57	1000.00	***0.0002	0.6236	**0.0053
	IL-12p70	1.94	4.56	1000.00	3.82	21.28	1000.00	1.68	7.85	1000.00	**0.0033	**0.0033	0.9055
	IFN- α	25.92	40.98	1000.00	21.43	1315.04	31.25	13.35	28.82	500.00	**0.0056	**0.0047	***<0.0001
	IL-1 β	1.46	127.82	1000.00	1.89	1189.93	250.00	1.22	217.29	1000.00	*0.0177	0.0770	0.0279
	GM-CSF	2.74	10.29	1000.00	3.44	108.49	125.00	3.30	12.27	500.00	0.1149	0.0935	0.4930
	IL-6	12.59	2847.25	1000.00	8.23	2353.76	1000.00	13.17	2514.88	1000.00	0.0658	*0.0176	0.4060
	IL-12p40	5.13	21.22	1000.00	16.51	36.75	1000.00	4.21	56.18	1000.00	**0.0023	*0.0457	0.1138
	IL-10	11.54	96.39	1000.00	5.84	128.96	1000.00	9.18	112.81	1000.00	*0.0144	0.8903	*0.0148
	CCL2	114.51	9550.86	1000.00	301.78	5878.50	500.00	219.85	5652.82	500.00	***0.0002	0.6236	**0.0053
	CXCL8	63.98	4628.43	1000.00	34.15	3806.51	500.00	63.73	1299.08	1000.00	0.1669	***<0.0001	***<0.0001
	PGE ₂	174.41	294.51	1000.00	74.34	117.64	250.00	16.65	57.48	62.50	***<0.0001	*0.0236	***<0.0001
GLA	CXCL10	25.02	245.67	1000.00	12.89	2481.00	250.00	14.66	3397.00	250.00	***<0.0001	***<0.0001	0.0703
	CCL4	36.20	9338.89	1000.00	52.00	6828.87	1000.00	40.33	6420.38	1000.00	0.3209	***<0.0001	***<0.0001
	CCL5	2579.37	5716.69	1000.00	1513.69	6242.68	1000.00	918.29	2854.60	1000.00	0.1839	***<0.0001	***<0.0001
	IFN- γ	1.83	31.31	1000.00	13.93	46.25	31.25	4.73	275.62	1000.00	0.0515	0.5833	***<0.0001
	TNF	41.20	90.59	1000.00	101.64	700.63	1000.00	22.15	351.05	1000.00	***<0.0001	***0.0005	***<0.0001
	IL-12p70	1.80	6.00	1000.00	2.08	30.42	31.25	1.21	89.54	250.00	**0.0062	*0.0284	*0.0237
	IFN- α	21.06	42.69	1000.00	21.06	1322.14	250.00	11.84	34.85	500.00	**0.0091	**0.0080	**0.0076
	IL-1 β	2.41	1425.75	1000.00	8.91	1562.25	250.00	3.63	1667.05	1000.00	0.2228	0.0611	**0.0079
	GM-CSF	1.48	22.10	1000.00	3.34	39.55	125.00	3.07	11.50	1000.00	0.0784	*0.0134	0.1961
	IL-6	18.13	9245.33	1000.00	9.31	4924.44	1000.00	13.75	6221.11	1000.00	***0.0001	**0.0022	***<0.0001
	IL-12p40	5.63	63.49	1000.00	6.20	70.13	1000.00	4.75	160.11	1000.00	*0.0153	0.2148	***0.0005
	IL-10	9.68	705.00	1000.00	8.52	475.31	1000.00	18.84	438.13	1000.00	0.2141	**0.0017	**0.0026
	CCL2	177.07	9909.23	1000.00	575.10	5726.38	125.00	147.12	4275.25	125.00	***<0.0001	***0.0005	***<0.0001
	CXCL8	66.86	8013.28	1000.00	19.59	3634.63	125.00	30.16	1604.63	1000.00	*0.0316	***<0.0001	***<0.0001
	PGE ₂	174.41	1817.03	1000.00	74.34	310.54	1000.00	20.29	322.76	1000.00	***<0.0001	0.1184	***<0.0001
R848	CXCL10	27.01	6207.86	0.20	13.12	6982.85	3.13	16.80	4629.75	1000.00	0.0079	0.1352	0.2075
	CCL4	64.83	11133.67	100.00	1303.32	7509.34	6.25	57.45	4931.45	1000.00	**0.0018	0.0838	***<0.0001
	CCL5	2503.74	6087.67	100.00	2812.48	5796.27	3.13	808.00	3403.80	12.50	0.6063	***<0.0001	***<0.0001
	IFN- γ	1.83	649.88	12.50	13.93	1205.75	25.00	4.73	2304.30	25.00	*0.0448	***<0.0001	***<0.0001
	TNF	22.12	3880.15	25.00	106.54	2027.31	12.50	22.13	1967.20	25.00	***0.0002	0.4638	***<0.0001
	IL-12p70	2.00	10.68	50.00	2.43	30.77	100.00	1.67	128.82	12.50	***<0.0001	***<0.0001	***<0.0001
	IFN- α	22.99	116.98	1.56	28.69	589.38	1.56	13.86	167.18	6.25	***<0.0001	***<0.0001	**0.0078
	IL-1 β	5.12	8790.84	50.00	20.44	3803.85	12.50	5.29	5472.60	12.50	***<0.0001	0.123	***<0.0001
	GM-CSF	2.07	29.91	50.00	4.20	34.58	12.50	4.42	32.05	50.00	0.5519	0.7408	0.4248
	IL-6	30.93	10156.18	50.00	193.22	6085.32	6.25	14.45	8518.30	12.50	***<0.0001	**0.0033	***<0.0001
	IL-12p40	7.70	407.00	12.50	9.47	478.94	12.50	4.25	1150.25	6.25	0.8557	***<0.0001	***<0.0001
	IL-10	10.67	2195.38	12.50	70.89	1652.82	6.25	7.67	1381.13	6.25	***0.0005	0.3275	***<0.0001
	CCL2	268.44	10275.11	50.00	1313.88	6216.66	1.56	248.37	5212.38	1.56	***0.0002	0.4638	***<0.0001
	CXCL8	96.57	9207.12	50.00	70.79	1495.50	12.50	36.51	467.75	12.50	***<0.0001	***<0.0001	***<0.0001
	PGE ₂	174.41	5132.93	12.50	74.34	116.93	100.00	25.26	74.42	6.25	***0.0002	0.8489	***0.0002
ODN	CXCL10	24.19	1698.78	0.10	10.60	3783.92	6.25	46.41	1116.45	12.50	0.2249	***0.0001	*0.0148
	CCL4	39.13	1287.25	50.00	28.26	1229.00	12.50	346.63	1401.43	12.50	0.0450	0.2523	0.5270
	CCL5	3437.82	6827.82	12.50	1567.06	6071.13	25.00	993.43	2618.82	6.25	0.7905	***0.0001	***0.0001
	IFN- γ	1.83	92.21	50.00	13.93	65.93	0.10	4.73	26.52	25.00	0.7653	**0.0057	*0.0277
	TNF	39.93	44.79	0.10	61.21	159.79	0.39	27.06	77.77	1.56	**0.0015	*0.0231	**0.0075
	IL-12p70	2.13	3.63	50.00	1.74	8.33	12.50	1.67	2.34	12.50	*0.0120	***0.0001	***0.0007
	IFN- α	30.54	31.15	3.13	30.55	160.14	6.25	9.85	33.29	12.50	***0.0007	***<0.0001	***0.0004
	IL-1 β	1.86	1728.29	25.00	8.71	115.53	0.20	5.24	17.80	50.00	*0.0331	**0.0058	*0.0156
	GM-CSF	2.91	7.32	25.00	1.83	7.28	12.50	3.17	6.11	12.50	0.4665	0.1486	0.3776
	IL-6	12.14	1692.84	25.00	75.18	787.49	0.20	28.60	41.03	50.00	*0.0408	***0.0010	**0.0018
	IL-12p40	6.87	98.65	6.25	4.90	31.82	50.00	26.01	26.01	0.00	*0.0115	**0.0021	*0.0156
	IL-10	9.78	287.52	6.25	27.89	63.21	12.50	7.37	29.69	12.50	**0.0029	***0.0009	***0.0001
	CCL2	121.53	8958.76	50.00	850.22	3622.37	12.50	231.66	944.98	25.00	***0.0001	***0.0001	***0.0001
	CXCL8	79.18	5059.90	50.00	54.04	659.78	50.00	27.36	154.74	50.00	***<0.0001	***<0.0001	*0.0282
	PGE ₂	174.41	286.31	50.00	74.34	157.53	50.00	25.03	41.16	6.25	***<0.0001	0.0597	***<0.0001

Figure 1

Highest in newborn whole blood

Highest in infant whole blood

Highest in adult whole blood

Figure 2

Figure 3

Figure 4

Figure 5